###### Strengths and limitations of this study

-   The BASIC study comprises a large cohort of critically ill children admitted to multiple PICUs in England, with biological samples linked to detailed demographic and clinical data regarding the intensive care course as well as 12-month follow up data collected using validated quality of life and behavioural questionnaires.

-   A careful process of clinical phenotyping has been undertaken to classify patients into infectious and non-infectious disease aetiologies. Samples have been stored for future proteomic and genomic analyses.

-   The process of deferred consent meant that severely ill patients recruited to the study who died before consent could be obtained, as well as children discharged from the PICU before families were approached for consent, were excluded, limiting the generalisability of our study findings.

-   We were unable to classify nearly a quarter of the patients by their infection aetiology most likely due to the use of a clinical definition as the gold standard for classification. Although we attempted to collect samples from prior to interventions, a significant proportion of children had been mechanically ventilated and treated with antibiotics by the time the transport team arrived at the local hospital.

Introduction {#s1}
============

Each year, nearly 20 000 children are admitted to paediatric intensive care units (PICUs) in the UK.[@R1] Considerable progress has been made in the understanding of paediatric critical illness and how best to provide organ support to improve outcomes, and mortality for children admitted to intensive care has reduced dramatically over the past four decades.[@R2] However, significant gaps remain in our current knowledge. In particular, short-term outcomes of emergency admissions to PICU remain suboptimal (mortality of 7%--8%), and relatively little is known about longer term morbidity in survivors.[@R3]

Severe infection is a leading cause of life-threatening illness in children. Yet, early identification of infection and further discrimination of whether it is bacterial (treatable with antibiotics) or viral remain a significant challenge in the acute/critical care setting.[@R5] Consequently, most, if not all, critically ill children are started and then remain on broad-spectrum antibiotics for several days; prolonged antibiotic use increases the risk of side-effects, increases cost and contributes to development of antimicrobial resistance.[@R7] A second challenge is that development of organ failure and progression to irreversible multiple organ failure is the final common pathway that leads to death or severe disability in children with critical illness, yet current approaches are reactive rather than proactive, using clinical and biochemical abnormalities to diagnose established organ failure rather than identify incipient organ failure.[@R9] Finally, while the future of interventional clinical trials in intensive care crucially hinges on early risk stratification, current severity of illness scores are designed for use in populations of patients rather than in individuals, and are designed to predict mortality, an uncommon and increasingly less relevant outcome of intensive care.[@R12]

The potential of multiomics technologies in unravelling the complex interactions between genes, proteins and biochemical reactions in other areas of medicine provides a strong indication that in order to fill existing gaps in our current knowledge in critical care, a comprehensive systems biology approach can be successfully applied to the study of large, diverse groups of sick children at an early stage of critical illness.[@R14] The Biomarkers of Acute Serious Illness in Children (BASIC) study is a multicentre collaborative study to identify genetic and biological pathways underlying the development of critical illness, organ failure and poor outcome (death or severe disability) in children requiring emergency intensive care.

Cohort description {#s2}
==================

Study aims {#s2a}
----------

The three key study aims were to: (1) develop a gene expression biomarker of bacterial infection which can be further developed as a simple point-of-care test to distinguish infections from other causes, and bacterial from viral infection, in critically ill children; (2) discover and validate biomarkers for early accurate detection of single and multiple organ failure that can predict organ failure earlier than the existing scores which are based on clinical data and laboratory tests that are already deranged; (3) identify biomarker-based strategies to help risk stratify critically ill children with diverse aetiologies at an early stage based on their predicted outcome in intensive care.

Study cohort {#s2b}
------------

BASIC is a multicentre, prospective, observational study involving a regional PICU transport service and four PICUs in southeast England (Great Ormond Street Hospital, St Mary's Hospital and the Royal London Hospital in London, and Addenbrookes' Hospital in Cambridge). Eligible patients were critically ill children aged 0--16 years requiring emergency transfer by the Children's Acute Transport Service (CATS) to a study PICU, with an indwelling catheter (arterial and/or central venous catheter for blood sampling and urinary catheter for urine sample collection). This simple and practical criterion has been shown in previous work to enrich the sample by selecting patients at high predicted risk of mortality, the median risk of death being 10% in the group of patients with an indwelling catheter, as compared with 8% in all transported children (as per CATS audit data). Children transported to other PICUs or non- PICU destinations, premature newborns (under 36-week corrected gestational age) and those with a known do-not-attempt-resuscitation order in place were excluded.

Patient recruitment and informed consent {#s2c}
----------------------------------------

All transported children were screened for eligibility by medical and nursing staff from the CATS team at first face-to-face patient contact. Eligible patients were recruited to the study and blood±urine samples were collected from indwelling catheters, coinciding with routine clinical sampling. Ethical approval was granted for consent to be deferred (also known as 'research without prior consent') due to the emergency setting, similar to previous clinical trials in paediatric emergency care; deferred consent has been shown to be acceptable to clinicians as well as participants.[@R22] A written informed consent was obtained by the research team in the admitting PICU from parents/guardians once the child's condition had stabilised, usually within 24--48 hours following PICU admission. As per ethical approval provided for deferred consent in our study, carers of children who died prior to approach for consent were excluded from the study. Parents/guardians could consent for full participation in the study (analysis of samples and clinical data already collected, further sample collection on the day of consent and data collection until the child's discharge from PICU, and contact to complete follow-up questionnaires at 12 months after PICU admission, if appropriate) or partial participation (analysis of samples and clinical data already collected but no further involvement), or refuse consent (samples and clinical data already collected to be discarded).

Sample collection {#s2d}
-----------------

Sample collection and transport procedures were devised based on previous work, the UK Biobank operating procedures and information from related sample handling validation studies (see [table 1](#T1){ref-type="table"}).[@R25] Blood and urine samples were collected at two points of time: during transport to PICU (time point 1) and after consent was obtained (time point 2). Time point 1 samples were transported on ice packs (4°C) to the admitting PICU where they were processed by the local research team. Samples were anonymised by means of a unique study number assigned by the CATS team to each recruited patient. Processed samples were stored at −80°C at individual sites and later transported to a central laboratory for further study analyses.

###### 

Samples and time points at which collected, processing and storage instructions, and total numbers of samples available

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                              1\                                                                                                        2\                                                                       3\                                                                                                  4\                                                                                                5\                   6\                7\
                                                              DNA                                                                                                       RNA                                                                      Plasma                                                                                              Serum                                                                                             Urine                Stool             Throat swab
  ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------- ----------------- -----------------
  Time points                                                 TP1\                                                                                                      TP1\                                                                     TP1\                                                                                                TP1\                                                                                              TP1\                 TP1\*\            TP1\*\
                                                              TP2                                                                                                       TP2                                                                      TP2                                                                                                 TP2                                                                                               TP2                  TP2               TP2

  Tube                                                        EDTA 2 mL                                                                                                 PAXgene 2 mL                                                             Sodium citrate 2 mL                                                                                 Separator gel 2 mL                                                                                Plastic tube 10 mL   Plastic tube      Plastic tube

  Processing                                                  Spun for 15 min at 2500 g at 4°C and plasma was transferred to cryostorage tubes to be frozen at - 80°C   Frozen pending extraction of RNA for gene expression analysis at −80°C   Spun for 15 min at 2500 g at 4°C and plasma supernatant aspirated and stored in aliquots at −80°C   Centrifuged for 15 min at 2500 g at 4°C and the serum aspirated and stored in aliquots at −80°C   Frozen at −80°C      Frozen at −80°C   Frozen at −80°C

  Number of patients with samples                             611                                                                                                       654                                                                      653                                                                                                 613                                                                                               480                  102               220

  Time from collection to processing in hours, median (IQR)   TP1: 22\                                                                                                  TP1: 21.9\                                                               TP1: 22\                                                                                            TP1: 22\                                                                                          N/A                  N/A               N/A
                                                              (12.9--44.6)\                                                                                             (12.9--44.5)\                                                            (12.7--44.5)\                                                                                       (12.9--44.6)\                                                                                                                            
                                                              TP2: 4.22\                                                                                                TP2: 3.5\                                                                TP2: 3.7\                                                                                           TP2: 3.5\                                                                                                                                
                                                              (0.5--19.7)                                                                                               (0.5--19)                                                                (0.5--19)                                                                                           (0.5--18.9)                                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Stool and throat swab TP1 samples were collected at paediatric intensive care unit (PICU) admission rather than during transport. TP1, time point 1 (during transport); TP2, time point 2 (after PICU admission, once consent had been obtained).

Clinical data {#s2e}
-------------

A standardised case report form and data collection manual with definitions and rules were produced for research staff at each PICU. Clinical data collected covered the key stages of the patient's pathway---intensive care referral and transport, PICU course and outcome. As shown in the online [supplementary table 1](#SP1){ref-type="supplementary-material"} and in [tables 2--4](#T2 T3 T4){ref-type="table"}, detailed clinical phenotyping information was collected, including reason for PICU referral/admission (infection, trauma, neurological, cardiac, respiratory and other), severity of illness (Paediatric Index of Mortality 2, PIMS-2 score), severity of organ failure (PEdiatric Logistic Organ Dysfunction, PELOD-2 score) on days 0, 1, 2 and 3, and outcome at discharge from PICU (death, severe disability). In addition, we used screening questions regarding general health and functional status and validated age- questionnaires (Child Behaviour Checklist and Pediatric Quality of Life Inventory, PedsQL) to assess the child's adaptive behaviour, general quality of life and functional outcome at 12 months after PICU admission, if appropriate.
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###### 

Demographic and clinical characteristics of cohort (n=674)

  Variable                                                           n (%)
  ------------------------------------------------------------------ -------------------------
  Male gender                                                        367 (54.5)
                                                                     13 (1.9)
  Ethnicity                                                          
   Asian                                                             77 (11.4)
   Black                                                             53 (7.9)
   White                                                             312 (46.3)
   Other                                                             40 (5.9)
   Missing                                                           192 (28.5)
  Age group                                                          
   0--1 month                                                        112 (16.6)
   1--11 months                                                      148 (22)
   1--4 years                                                        212 (31.5)
   5--12 years                                                       132 (19.6)
   \>12 years                                                        55 (8.2)
   Missing                                                           15 (2.2)
  Consanguinity                                                      22 (3.3)
   Missing                                                           203 (30.1)
  Comorbidities present                                              342 (51)
   Missing                                                           42 (6.2)
  Comorbidities\*                                                    
   Respiratory                                                       110 (16.3)
   Cardiac                                                           73 (10.8)
   Neurological                                                      134 (19.9)
   Genetic/syndrome                                                  62 (9.2)
   Metabolic/endocrine                                               33 (4.9)
   Haematological/oncological                                        13 (1.9)
   Multisystem disorder                                              8 (1.2)
   Other                                                             103 (15.3)
  Gestational age, median (IQR)†                                     38 (36--40) (n=245)
  Time from onset of symptoms to first contact with transport team   
   Less than 6 hours                                                 126 (18.7)
   6--24 hours                                                       169 (25.1)
   24--72 hours                                                      168 (24.9)
   3--7 days                                                         123 (18.2)
   \>7 days                                                          73 (10.8)
   Missing                                                           15 (2.2)
  PCPC status (prior to PICU admission)                              
   Normal                                                            434 (64.4)
   Mild disability                                                   38 (5.6)
   Moderate disability                                               52 (7.7)
   Severe disability                                                 64 (9.2)
   Missing                                                           86 (12.8)
  POPC status (prior to PICU admission)                              
   Normal                                                            433 (64.2)
   Mild disability                                                   38 (5.6)
   Moderate disability                                               57 (8.5)
   Severe disability                                                 62 (9.2)
   Missing                                                           84 (12.5)
  Acuity during transport to PICU                                    
   Invasively ventilated                                             573 (85)
   Inhaled nitric oxide                                              25 (3.7)
   Received\>40 mL/kg fluid bolus                                    51 (7.6)
   Vasoactive agents                                                 260 (38.6)
   Blood product transfusion                                         13 (1.9)
   Maximum vasoactive-inotropic score, median (IQR)                  20 (10--65) (n=243)
  Fixed and dilated pupils                                           6 (0.9)
  PELOD-2 score, median (IQR)                                        6 (4--8) (n=674)
  PIM-2 mortality risk, median (IQR)                                 3.8% (1.4--5.3) (n=674)

\*Same child may have comorbidities of different groups.

†Gestational age was collected only for children\<2-year old.

PCPC, paediatric cerebral performance category; PELOD-2, PEdiatric Logistic Organ Dysfunction; PICU, paediatric intensive care unit; PIM-2, Paediatric Index of Mortality---2; POPC, paediatric overall performance category.

###### 

Course during intensive care stay (N=674)

  Variable                                              n (%)
  ----------------------------------------------------- ----------------------
  Type of admission                                     
   Unplanned, after surgery                             19 (2.8)
   Unplanned, other                                     650 (96.5)
   Missing                                              5 (0.7)
  Number of hours invasively ventilated, median (IQR)   87 (40--168) (n=669)
  Number of hours on vasoactive agents, median (IQR)    0 (0--48) (n=644)
  Number of hours on inhaled nitric oxide, mean (SD)    4.18 (19.74) (n=37)
  Number of hours on ECLS, mean (SD)                    3.93 (30.07) (n=15)
  Number of hours on CRRT, mean (SD)                    2.6 (26.87) (n=12)
  Abnormal brain imaging                                116 (17.2)
   Missing                                              10 (1.5)
  Abnormal neurophysiology                              99 (14.7)
   Missing                                              7 (1.0)
  Cardiac arrest during this admission                  12 (1.8)
   Missing                                              7 (1.0)
  PICU discharge status                                 
   Died                                                 27 (4.0)
   Alive                                                636 (96)
   Missing                                              11 (1.6)
  Discharge location                                    
   Home                                                 18 (2.7)
   Hospice                                              5 (0.7)
   Other                                                10 (1.5)
   Other hospital                                       312 (46.3)
   Same hospital                                        291 (43.2)
   Missing                                              37 (5.6)
  Discharge POPC                                        
   Normal                                               358 (53.1)
   Mild disability                                      54 (8)
   Moderate disability                                  46 (6.8)
   Severe disability                                    70 (10.4)
   Coma/vegetative state                                1 (0.1)
   Missing                                              145 (21.5)
  Discharge PCPC                                        
   Normal                                               363 (53.9)
   Mild disability                                      54 (8)
   Moderate disability                                  41 (6.1)
   Severe disability                                    69 (10.2)
   Coma/vegetative state                                1 (0.1)
   Brain death                                          1 (0.1)
   Missing                                              145 (21.5)
  Ventilator free days at day 30, median (IQR)          25 (22--27) (n=642)
  PICU free days at day 30, median (IQR)                24 (19--26) (n=642)

PCPC, paediatric cerebral performance category; PICU, paediatric intensive care unit; POPC, paediatric overall performance category.

###### 

Classification of reasons for paediatric intensive care unit admission (n=669)

  Classification                                  n (%)
  ----------------------------------------------- ------------
  Definite bacterial infection                    61 (9.1)
  Definite viral infection                        146 (22)
  Probable bacterial infection                    60 (8.9)
  Probable viral infection                        27 (4.0)
  Inconclusive for bacterial or viral infection   159 (23.6)
  Non-infectious condition                        215 (31.9)
  Type of non-infectious conditions:              n=215
  Respiratory/airway                              45 (19.5)
  Cardiac                                         57 (27.4)
  Neurological                                    51 (23.7)
  Trauma/head injury                              22 (10.2)
  Endocrine/metabolic                             13 (6.0)
  Other                                           28 (13.1)

Outcome measures {#s2f}
----------------

### Primary {#s2f1}

1.  Diagnosis of bacterial infection by laboratory tests (culture, molecular diagnostics) within the first 28 days or prior to PICU discharge.

2.  Multiorgan failure---failure of two or more organs using the PELOD-2 score within the first 28 days or prior to PICU discharge.

3.  Poor outcome defined as mortality or development of a new severe disability at intensive care unit discharge.

### Secondary {#s2f2}

1.  Long-term health-related quality of life assessed at 12 months by the age-appropriate PedsQL questionnaire completed by parent proxy.

2.  Long-term behavioural outcome assessed at 12 months by the age-appropriate Child Behaviour Checklist completed by parent proxy.

Sample size {#s2g}
-----------

No formal sample size calculations were performed, but we aimed to recruit adequate numbers of patients with different reasons for intensive care admission as well as those experiencing the primary outcomes (50--80 patients per group of interest). According to previous audit data, we estimated that we could recruit up to 800 patients over the study period.

Sample analyses {#s2h}
---------------

In the first phase of sample analyses, we will address the first key study aim, namely the development of a gene expression biomarker to distinguish infections from other causes, and bacterial from viral infection. We will not limit our analyses to a preselected list of biomarkers, instead a hypothesis-free approach will be pursued. Whole blood was collected in PAXgene blood RNA tubes (PreAnalytiX), and later extracted using PAXgene blood RNA kits (PreAnalytiX). RNA was shipped to the Oxford Genomics Center for analysis on HumanHT-12 V.4 expression Beadarrays (Illumina). Other samples will be stored for future analyses, and in further phases, we will consider the use of genomics, rapid throughput proton nuclear magnetic resonance spectroscopy and mass spectrometry techniques to explore the role of protein biomarkers, as well as undertaking metabolomic analyses. DNA will be used for genotyping of genes implicated in sepsis or critical illness, enabling linking of genetic and transcriptomic information.

Study organisation {#s2i}
------------------

The study was conducted under the leadership of a BASIC study management group comprising the investigators with overall responsibility for protocol design, study conduct and publication. Imperial College serves as the coordinating centre for sample and informatics analyses.

Findings {#s3}
========

During the study period of 33 months (1 April 2014--7 December 2016), 2333 children were transported to the participating PICUs by the CATS team. As shown in [figure 1](#F1){ref-type="fig"}, although 1054 patients were recruited to the BASIC study by the CATS team, 37 were ineligible since they were not eventually admitted to a study PICU. Consent for participation was obtained from parents/guardians of 674 children (66.1% of the 1017 children admitted to a study PICU). The main reason for not obtaining consent from patients was death or discharge of the patient from the PICU prior to being approached by the research team (137/1017, 13.5%). Parents/guardians refused consent in 114/1017 (11.2%).

![Flow chart of recruitment to the Biomarkers of Acute Serious Illness in Children study.](bmjopen-2018-024729f01){#F1}

Cohort characteristics are shown in [table 2](#T2){ref-type="table"}. An overview of samples and time points at which collected, processing and storage instructions, and total numbers of samples stored is summarised in [table 1](#T1){ref-type="table"}.

Details regarding the PICU stay and short-term outcomes for the children enrolled are shown in [Table 3](#T3){ref-type="table"}.

At the end of the PICU stay, study patients were classified into one of six groups based on their infection status as a reason for admission (non-infectious condition; definite bacterial, definite viral, probable bacterial and probable viral infections; and unable to determine infection status) as shown in [table 4](#T4){ref-type="table"}.

We used an algorithm as described previously to perform this classification (online [supplementary figure 1](#SP1){ref-type="supplementary-material"}).[@R27] The classification was performed by two investigators (JCW and YF) and a random sample of 10% of records was checked by one investigator (PR). Any queries arising during this classification were resolved by discussion with PR.

Patient and public involvement {#s3a}
------------------------------

Parents of children previously transported to an intensive care unit were involved in the pilot testing of the 12-month follow-up questionnaires and provided input into the choice of the questionnaires. Although there was no formal involvement of parents/public in the development of the research question and outcome measures chosen, clinicians within the research team identified the research question and outcomes as being important for patients from informal discussions with patients/parents.

Strengths and limitations {#s3b}
-------------------------

The BASIC study comprises a large cohort of critically ill children admitted to multiple PICUs in England, with biological samples linked to detailed demographic and clinical data regarding the intensive care course as well as 12-month follow-up data collected using validated quality of life and behavioural questionnaires. A careful process of clinical phenotyping has been undertaken to classify patients into infectious and non-infectious disease aetiologies. Samples have been stored for future proteomic and genomic analyses.

Recruitment in an emergency setting {#s3c}
-----------------------------------

One of the unique strengths of this cohort is the timing and extensive nature of sample and clinical data collection in a population of critically ill children. In contrast to similar previous cohorts, we chose to standardise the timing of sample collection to the point of first contact with an intensive care team early in the course of critical illness, rather than after PICU admission. This provides the opportunity to collect biological samples at the earliest time point as practically possible during critical illness, when the confounding effect of a dynamically evolving pathophysiology and the influence of critical care interventions such as mechanical ventilation and vasoactive agent treatment may be ameliorated. In addition, even though patients may first present to hospitals at various stages of their critical illness, by standardising sample collection to the earliest possible time point, we attempted to generate a more homogenous cohort than possible if patients were recruited at various time points after PICU admission.

Consent model {#s3d}
-------------

Recognising that asking parents/guardians to consent to a research study in a busy emergency setting (where the priority for the transport team is to perform life-saving interventions) may result in a less than ideal informed consent process, we chose to defer written consent until after PICU admission, when the child's clinical condition had stabilised. We provided parents with the option for either full or partial participation in the study, or for refusal of consent. Although we saw a low proportion of refusal of consent (\~10%), practical challenges of providing 7 days a week research nurse cover on the units to approach recruited participants meant that a significant proportion were not approached for consent resulting in collected samples being destroyed.

Limitations {#s3e}
-----------

The process of deferred consent resulted in bias: 31 children who were recruited to the study died before consent could be obtained from families, which, as per approved ethical procedures, resulted in their exclusion from the study. Due to this exclusion, severely ill patients were excluded limiting the generalisability of our study findings. Similarly, 70 children were recruited to the study but were discharged from the PICU before families were approached for consent, resulting in their exclusion. Despite the high level of detail contained in the clinical database, we found that four patients were excluded due to missing data on key data such as their outcome and infection status. In addition, we were unable to classify nearly a quarter of the patients by their infection aetiology most likely due to the use of a clinical definition as the gold standard for classification. Although we attempted to collect samples from prior to interventions, a significant proportion of children had been mechanically ventilated and treated with antibiotics by the time the transport team arrived at the local hospital.
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